BEVONIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H28NO3
Molecular Weight	354.4626
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

C[N+]1(C)CCCCC1COC(=O)C(O)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=UHUMRJKDOOEQIG-UHFFFAOYSA-N

InChI=1S/C22H28NO3/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3/q+1

HIDE SMILES / InChI

Molecular Formula	C22H27NO3
Molecular Weight	353.4547
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://infomeds.net/akabel.html | http://www.genome.jp/dbget-bin/www_bget?dr:D01532

Bevonium is a parasympatolytic antimuscarinic compound. It possesses spasmolytic properties. The use of the drug is discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D01532	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Spasm 18 Sources: http://infomeds.net/akabel.html	Primary		Approved 8429	ACABEL Approved Use Acabel (Bevonium methyl sulfate) is parasympatolytic drug with well balanced action on the neuromuscular device. Possesses broncho-and spasmolytic properties. Acabel is indicated for bronchial asthma, peptic ulcer of a stomach and duodenum, pylorospasm, postoperative spastic pains, spastic locks, cholestasia, cholecystitis, cholangitis, postcholecystectomy syndrome, chronic hepatopathy and pancreatitis, various diseases of kidneys and urinary tract. Prenatal and puerperal pains, dysmenorrhea, adnexitis, endometritis, dysfunction of ovaries, tumor of genitalias.

PubMed

Title	Date	PubMed
[Effect of piribenzil methylsulfate (CG-201) on ureteral activity].	1968 Nov	5752067
[Bevonium methylsulfate (CG 201) in the treatment of enuresis and bladder neurosis].	1970 Jul	5465265
Letter: A double-blind trial of bevonium methylsulphate on gastric acid secretion in man.	1976 Jan 3	766231

Patents

Sample Use Guides

In Vivo Use Guide

Form of release of medicine: Acabel: tablets on 50 mg, candles on 30 pieces in packaging. Acabel compositum: tablets (bevonium methyl sulfate — 0,05 g, Dipyronum — 0,25 g); candles (bevonium methyl sulfate — 0,03 g, Dipyronum — 1 g); ampoules on 5 ml (bevonium methyl sulfate — 0,0025 g, Dipyronum — 2,5 g). Use: Acabel appoint inside 1 — 2 tablet 2 — 3 times a day, candles (only the adult) — on 1 piece 2 — 3 times a day. Intramusculary or intravenously slowly enter on 1/2 — 1 ampoule of an akabel difficult 3 once a day.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:43:08 GMT 2023` Edited by `admin` on `Fri Dec 15 15:43:08 GMT 2023`
Record UNII	34B0471E08
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BEVONIUM

Common Name

English

2-(HYDROXYMETHYL)-1,1-DIMETHYLPIPERIDINIUM BENZILATE

Systematic Name

English

BEVONIUM CATION

Common Name

English

Bevonium [WHO-DD]

Common Name

English

PIPERIDINIUM, 2-(((2-HYDROXY-2,2-DIPHENYLACETYL)OXY)METHYL)-1,1-DIMETHYL-

Systematic Name

English

BEVONIUM ION

Common Name

English

Classification Tree Code System Code

WHO-VATC

QA03AB13